|
Main findings of epigenetic therapy in cervical cancer |
| Lack of response to DNA methylation inhibitor 5-aza-2-deoxycytidine as a single agent in advanced or recurrent cervical cancer* |
| Response rate of 38.1% with the DNA methylation inhibitor 5-aza-2-deoxycytidine plus cisplatin in advanced or recurrent cervical cancer* |
| Demethylation and reactivation of the expression of several tumor suppressor genes in the tumors of cervical cancer patients in a phase I trial of the DNA methylation inhibitor hydralazine |
| Sustained stabilization of disease in a patient with cervical cancer treated within a phase I trial of the HDAC inhibitor MS-275 |
| Major response in a patient with cervical cancer being treated with the HDAC inhibitor valproic acid followed by a single dose of epirubicin within a phase I trial |
| H3 and H4 hyperacetylation as well as inhibition of deacetylase activity in the tumors of cervical cancer patients with cervical cancer in a phase I trial of the HDAC inhibitor magnesium valproate |
| Ongoing phase II trial of the combination of hydralazine and magnesium valproate added to cisplatin chemoradiation in FIGO stage IIIB patients |
|
*DNA methylation was not analyzed in these trials. |
Dueñas-González et al. Molecular Cancer 2005 4:38 doi:10.1186/1476-4598-4-38 |